Talking Euretina

Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.

Prof. Zohar Habot-Wilner (Tel Aviv University) chairs a rich discussion with Prof. Sofia Androudi (University of Thessaly, Greece) and Prof. Sarah Touhami (University of Sorbonne) on managing retinal and uveitic diseases during pregnancy. They explore safe diagnostic tools, therapeutic dilemmas like Ranibizumab vs. Ozurdex, and the effects of pregnancy-related hormonal shifts—highlighting the importance of multidisciplinary collaboration in high-risk cases

What are hyperreflective foci, and why do they matter in AMD? Prof. Stella Vujosevic is joined by Prof. Christine Curcio (University of Alabama at Birmingham) and Prof. Srinivas Sadda (Doheny Eye Institute, UCLA) to explore their significance—from donor eye histology to OCT imaging. They discuss key biomarkers, clinical implications, and how HRF can help guide treatment decisions in age-related macular degeneration

What causes central serous chorioretinopathy (CSC), and how should it be managed? In this episode, experts Camiel Boon, Sobha Sivaprasad, and Gemmy Cheung discuss the latest insights into CSC and the pachychoroid spectrum, including new imaging findings, risk factors, and treatment options like PDT, laser, and anti-VEGF

Uveal melanoma remains a significant challenge, with genetic alterations playing a crucial role in treatment decisions. In this episode, Prof Jens Folke Kiilgaard (Denmark) and Dr Emine Kilic (Netherlands) join Prof Antonia Joussen (Germany) to explore why metastases persist despite primary tumor treatment, the limitations of checkpoint inhibitors, and the latest on Tebentafusp and Darovasertib. We also discuss the role of adjuvant and neoadjuvant therapies and emerging T-cell therapies. Join us for an insightful discussion on the future of uveal melanoma treatment

In this episode, Chair Alistair Laidlaw (UK) chats to Mario Romano (Italy) and Stratos Gotzaridis (Greece) about some of the considerations and complications surrounding the use of intraocular tamponades. They also discuss the upcoming Special Focus Meeting in Athens which will centre on vitreoretinal surgery (VR)

In this final episode of highlights from the Barcelona congress 2024, we’ll hear from Dr Arshad Khanani (USA) about clinical trials, long term-data and the importance of personalising the treatment to the patient

In this second episode looking at highlights from the Barcelona congress, we'll hear about AI and sustainability in ophthalmology from Prof Jean-Francois Korobelnik of University Hospital Bordeaux

Barcelona, We love you! Over the next few episodes, we'll be hearing from 3 different sub-specialty experts about their favourite picks from the excellent Euretina Congress this year. This week, we hear from Ms. Rumana Hussain, Consultant Ophthalmologist specialising in Ocular Oncology and VR surgery at Liverpool University Trust Foundation Hospitals

In this episode, Prof Nicole Eter (Germany) speaks with Dr Yousif Subhi, this year's Ophthalmologica lecture about his work in meta-analyses, evidence synthesis, determination of best-practice, and clinical research